➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
Medtronic
Johnson and Johnson
McKesson
Mallinckrodt

Last Updated: November 28, 2020

DrugPatentWatch Database Preview

Cangrelor - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for cangrelor and what is the scope of freedom to operate?

Cangrelor is the generic ingredient in one branded drug marketed by Chiesi and is included in one NDA. There are eight patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Cangrelor has one hundred and six patent family members in forty-one countries.

There are three drug master file entries for cangrelor. One supplier is listed for this compound.

Recent Clinical Trials for cangrelor

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Scott R MacKenzie FoundationPhase 4
University Medical Centre LjubljanaPhase 4
Chiesi Slovenija, d.o.o.Phase 4

See all cangrelor clinical trials

Pharmacology for cangrelor
Paragraph IV (Patent) Challenges for CANGRELOR
Tradename Dosage Ingredient NDA Submissiondate
KENGREAL POWDER;INTRAVENOUS cangrelor 204958 2019-06-24

US Patents and Regulatory Information for cangrelor

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Chiesi KENGREAL cangrelor POWDER;INTRAVENOUS 204958-001 Jun 22, 2015 RX Yes Yes   Start Trial   Start Trial   Start Trial
Chiesi KENGREAL cangrelor POWDER;INTRAVENOUS 204958-001 Jun 22, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Chiesi KENGREAL cangrelor POWDER;INTRAVENOUS 204958-001 Jun 22, 2015 RX Yes Yes   Start Trial   Start Trial   Start Trial
Chiesi KENGREAL cangrelor POWDER;INTRAVENOUS 204958-001 Jun 22, 2015 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for cangrelor

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1007094 15C0060 France   Start Trial PRODUCT NAME: CANGRELOR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,NOTAMMENT UN SEL TETRASODIQUE; REGISTRATION NO/DATE: EU/1/15/994/001 20150323
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Medtronic
McKinsey
Dow
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.